The primary biliary epithelial cells of patients with primary sclerosing cholangitis (PSC) seem to be hyper-responsive to intestinal endotoxins. The resulting endotoxin intolerance could contribute to ...

Distinct lipid changes in primary biliary cholangitis may signal inflammation and fibrosis. Discover how these findings could ...

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory. Learn more ...

The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes ...

In this video, Marlyn Mayo, MD, discusses “revealing” data from the eMPower trial that showed a digital mind-body wellness program improved mental health and fatigue in primary sclerosing cholangitis ...

First indication for chronic pruritis in PBC where 70% of patients suffer from intractable and debilitating itching with limited treatment options BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / ...

Intestinal metaplasia is also involved in the pathogenesis of biliary diseases. For example, in chronic cholangitis such as hepatolithiasis, intestinal metaplasia with goblet cells occurs, and MUC2 is ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...

Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct ...

FOSTER CITY, Calif., October 23, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with ...

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...